Anything but Black and White - Racial Disparities in Prostate Cancer

Daniel George | September 11, 2019

Race is a complex topic in any setting, but in healthcare, it is particularly challenging given the influence of social, lifestyle, and structural determinants associated with racial populations. Make no mistake, race matters in cancer outcomes; in prostate cancer, in particular, year after year black men consistently die at nearly 2.5 times the rate of white men with the same disease.1


Daniel George

Daniel George, MD is Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine and leads the Duke Prostate and Urologic Cancer Center. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology. Daniel George has led the Duke site for the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium since 2006.

Clinical Conversations by Experts
Everyday Urology - Oncology Insights
Publications focusing on urologic cancer treatments through original manuscripts
By William C. Carithers, Jr., PHD
Published Date: June 2017

Focusing on The First and Only FDA Approved Targeted Alpha Therapy Radium-223 in the Treatment of mCRPC

The Tenth Symposium on Targeted Alpha Therapy (TAT-10) opened on Wednesday, May 31, 2017 in Kanazawa Japan. The symposium was jointly organized by the Joint Research Centre (JRC) of the European Commission and Kanazawa University
By Phillip J. Koo, MD
Published Date: March 2017

More than 90% of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases which leads to a significant increase in morbidity and mortality.1,2 Patients with metastatic prostate cancer and bone involvement have only a 3% five-year survival, whereas the five-year survival of patients without bone metastases is 56%.
By Neal Shore, MD, FACS
Published Date: June 2016

Prostate cancer is the most common malignancy among US men, with an estimated annual incidence of 180,890, accounting for one in five new cancer cases in men.1 The second-most common cause of cancer death in US men, prostate cancer is expected to claim the lives of 26,120 men in this country in 2016.1
Library Resources
The State-of-the-Evidence in Brief Reviews by Experts
Written by Christopher J.D. Wallis, MD, PhD and Zachary Klaassen, MD, MSc
December 3, 2019
Radiopharmaceuticals are pharmaceutical agents containing radioisotopes and emitting radiation that may be used for diagnostic or treatment purposes. The ALSYMPCA trial was the first to demonstrate that radiopharmaceuticals could improve overall survival, in addition to skeletal-related events, in patients with metastatic castrate-resistant prostate cancer. On the basis of this observation, there is an ongoing effort to identify molecular targets for linkage to radiopharmaceuticals.
Written by Christopher J.D. Wallis, MD PhD and Zachary Klaassen, MD, MSc
February 27, 2020

Patients with advanced prostate cancer are at significant risk of skeletal-related events (SREs) due to a complex interplay between bone health and prostate cancer due to cancer biology and the predilection of prostate cancer to spread to bone, the toxicity of prostate cancer treatments, and shared epidemiology of the two conditions.


Written by Christopher J.D. Wallis, MD, PhD and Zachary Klaassen, MD, MSc
April 16, 2019
Prostate cancer exhibits a wide spectrum of disease behaviour. Despite the majority of cases presenting with relatively indolent biologic behaviour, prostate cancer remains the second leading cause of cancer-related death in the United States, behind only lung cancer.
Conference Coverage
Conference Highlights from Recent Conference Coverage
Presented by Catherine H. Marshall, MD, MPH
 Immune modulation may be enhanced by radiation therapy through a variety of mechanisms, including via enhanced display of tumor-associated antigens. Furthermore, radiopharmaceutical agents have been shown to upregulate tumor antigens in prostate cancer models,1
Presented by Silke Gillessen, MD
San Francisco, CA ( Silke Gillessen, MD presented a study comparing two different dosing frequencies of Denusomab in patients with castration-resistant PC, and evaluating the rate of hypocalcemia in the two treatment options.
Presented by Matthew R. Smith, MD, Ph.D.
Munich, Germany ( Radium-223 is an alpha emitter which selectively treats bone metastases with alpha radiation.1 In a recent GU ASCO oral presentation, a radium-223 pharmacodynamic study demonstrated
Presented by Matthew R. Smith, MD, Ph.D.
Munich, Germany ( As has been the trend in management of advanced solid malignancies, there has been increasing interest